Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.8.3869

Prognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study  

Inal, Ali (Department of Medical Oncology, Dicle University)
Kaplan, M. Ali (Department of Medical Oncology, Dicle University)
Kucukoner, Mehmet (Department of Medical Oncology, Dicle University)
Urakci, Zuhat (Department of Medical Oncology, Dicle University)
Guven, Mehmet (Department of Internal Medicine, Dicle University)
Nas, Necip (Department of Internal Medicine, Dicle University)
Yunce, Muharrem (Department of Biochemistry, Dicle University)
Isikdogan, Abdurrahman (Department of Medical Oncology, Dicle University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.8, 2012 , pp. 3869-3872 More about this Journal
Abstract
Background: The majority of patients with gastric cancer in developing countries present with advanced disease. Systemic chemotherapy therefore has limited impact on overall survival. Patients eligible for chemotherapy should be selected carefully. The aim of this study was to analyze prognostic factors for survival in advanced gastric cancer patients undergoing first-line palliative chemotherapy. Methods: We retrospectively reviewed 107 locally advanced or metastatic gastric cancer patients who were treated with docetaxel and cisplatin plus fluorouracil (DCF) as first-line treatment between June 2007 and August 2011. Twenty-eight potential prognostic variables were chosen for univariate and multivariate analyses. Results: Among the 28 variables of univariate analysis, nine variables were identified to have prognostic significance: performance status, histology, location of primary tumor, lung metastasis, peritoneum metastasis, ascites, hemoglobin, albumin, weight loss and bone metastasis. Multivariate analysis by Cox proportional hazard model, including nine prognostic significance factors evident in univariate analysis, revealed weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level to be independent variables. Conclusion: Performance status, weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level were identified as important prognostic factors in advanced gastric cancer patients. These findings may facilitate pretreatment prediction of survival and can be used for selecting patients for treatment.
Keywords
Gastric cancer; first-line chemotherapy; prognostic factors;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Andreyev HJ, Norman AR, Oates J, Cunningham D (1998). Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer, 34, 503-9.   DOI
2 Chau I, Norman AR, Cunningham D, et al (2004). Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol, 15, 2395-403.
3 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90   DOI
4 Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8, 163-8.   DOI   ScienceOn
5 Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH (2005). Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol, 23, 175-83.   DOI
6 Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. JCO, 24, 2137-50.   DOI   ScienceOn
7 Kanagavel D, Pokataev IA, Fedyanin MY, et al (2010). A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol, 21, 1779-85.   DOI
8 Kim JG, Ryoo BY, Park YH, et al (2008). Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol, 61, 301-7
9 Krishnan S, Rana V, Janjan NA, et al (2006). Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 107, 2589-96.   DOI   ScienceOn
10 Lee J, Lim T, Uhm JE, et al (2007). Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol, 18, 886-91.   DOI
11 Maroufizadeh S, Maroufizadeh S, Hajizadeh E, Baghestani AR, Fatemi SR (2011). Multivariate analysis of prognostic factors in gastric cancer patients using additive hazards regression models. Asian Pac J Cancer Prev, 12, 1697-702.
12 Mitry E, Douillard JY, van Cutsem E, et al (2004). Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial. Ann Oncol, 15, 1013-7.   DOI
13 Murad AM, Santiago FF, Petroianu A, et al (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer, 72, 37-41.   DOI   ScienceOn
14 Roth AD, Fazio N, Stupp R, et al (2006). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol, 25, 3217-23.
15 Park SH, Lee J, Lee SH, et al (2006). Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based firstline chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol, 57, 91-6.   DOI
16 Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995). Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 71, 587-91.   DOI
17 Roshanaei G, Ghannad MS, Jafarabadi MA, Faradmal J, Sadighi S (2011). Prognostic impact of risk factors in patients with gastric cancer in Iran. Asian Pac J Cancer Prev, 12, 3005-8.
18 Roshanaei G, Ghannad MS, Jafarabadi MA, Faradmal J, Sadighi S (2011). Prognostic impact of risk factors in patients with gastric cancer in Iran. Asian Pac J Cancer Prev, 12, 3005-8.
19 Sadeghi B, Arvieux C, Glehen O, et al (2000). Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer, 88, 358-63.   DOI
20 Sougioultzis S, Syrios J, Xynos ID, et al (2010). A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol, 21, 1779-85.   DOI
21 Tsujitani S, Oka S, Suzuki K, et al (2001). Prognostic factors in patients with advanced gastric cancer treated by noncurative resection: a multivariate analysis. Hepatogastroenterology, 48, 1504-8.
22 Yoshida M, Ohtsu A, Boku N, et al (2004). Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol, 34, 654-9.   DOI
23 Van Cutsem E, Moiseyenko VM, Tjulandin SA, et al (2006). V325 Study Group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol, 24, 4991-7.   DOI   ScienceOn
24 Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol, 24, 2903-9   DOI